, Volume 72, Issue 8, pp 1011–1028

Management of Metastatic Castration-Resistant Prostate Cancer

Recent Advances


  • Deborah Mukherji
    • Institute of Cancer Research
  • Andrew Eichholz
    • Institute of Cancer Research
    • Institute of Cancer Research
Leading Article

DOI: 10.2165/11633360-000000000-00000

Cite this article as:
Mukherji, D., Eichholz, A. & De Bono, J.S. Drugs (2012) 72: 1011. doi:10.2165/11633360-000000000-00000


Metastatic prostate cancer remains a considerable therapeutic challenge; however, advances in clinical research have resulted in five new treatments in the last 2 years. The immunotherapy sipuleucel-T, the cytotoxic cabazitaxel, the androgen biosynthesis inhibitor abiraterone acetate, the radioisotope al-pharadin and the anti-androgen MDV3100 have all been shown to improve overall survival in randomized phase III studies for patients with metastatic castration-resistant prostate cancer. The therapeutic strategies of targeting androgen-receptor signalling and other key intracellular pathways involved in tumour progression and treatment resistance are yielding promising results. Agents such as the dual vascular endothelial growth factor receptor/MET inhibitor cabozantinib, the clusterin inhibitor custirsen and the Src inhibitor dasatinib have shown encouraging results in phase II studies. Novel immunotherapeutics such as prostate-specific membrane antigen-directed therapy and the anti-cytotoxic T lymphocyte-associated receptor 4 (CTLA4) antibody ipilimumab are also under investigation. Optimal methods of treatment selection, combination and sequencing have yet to be determined.

Copyright information

© Springer International Publishing AG 2012